Belvedere Trading’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

Belvedere Trading’s Portfolio GNOM Stock Details GNOM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$490K	Buy	+8,626	New	+$411K	﹤0.01%	337

Other funds holding GNOM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

OAM

Oppenheimer Asset Management New York $9.63B AUM 30.32% 1-Year Est. Return

AAP

Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return

CFD

Creative Financial Designs Kokomo, Indiana $2.1B AUM 23.1% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

FIA

Foundations Investment Advisors Phoenix, Arizona $9.72B AUM 29.41% 1-Year Est. Return

Belvedere Trading's GNOM Position: Q2 2026 in Review

Belvedere Trading opened a new position in Global X Genomics & Biotechnology ETF (GNOM) in Q2 2026: 8,626 shares worth $490K. The stake represents ﹤0.01% of the portfolio and ranks #337 among its holdings.

48 funds tracked by Wall St. Rank hold GNOM as of Q2 2026.

Belvedere Trading held 8,626 shares of Global X Genomics & Biotechnology ETF worth $490K as of Q2 2026.
Global X Genomics & Biotechnology ETF was a new Belvedere Trading position in Q2 2026.
Global X Genomics & Biotechnology ETF made up ﹤0.01% of Belvedere Trading's portfolio in Q2 2026, its #337 holding.
48 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q2 2026.

Based on Belvedere Trading's 13F filing for Q2 2026, filed 31 Jul 2026.